Cancer survivor Laurie Adami reflects on her experience participating in a clinical trial that ultimately contributed to the March 2021 approval of a CAR-T cell therapy for follicular lymphoma.

by Laurie Adami

In recent months, drugmakers have announced they are withdrawing indications for four immune checkpoint inhibitors in consultation with the Food and Drug Administration. What does this mean for patients who are taking these drugs?

by Anna Goshua

Researchers are studying the effectiveness of drugs for treating COVID-19 in cancer patients who have been infected with the coronavirus.

by Marcus A. Banks

Two immune checkpoint inhibitors are now approved for treatment of some people with advanced breast cancer, but trial results have raised some questions.

by Anna Goshua

A study shows that a blood test for gastrointestinal tumor mutations gave results in a third of the time needed for solid tissue testing. Patients who received the blood test were more likely to enroll in clinical trials.

by Emma Yasinski

The Food and Drug Administration approved an immunotherapy drug for tumors with high tumor mutational burden regardless of tumor type. But some medical oncologists say it's not clear the biomarker is valid across all cancer types.

by Anna Azvolinsky

A trial of the targeted therapy Tagrisso (osimertinib) for early-stage lung cancer finds that patients who take it go longer without having a cancer recurrence. Whether that should change clinical practice is under discussion.

by Ashley P. Taylor

COVID-19 slowed or stopped enrollment in some cancer clinical trials.

by Kate Yandell

Cancer patients and their families share stories of fear, love and uncertainty as they find new ways to support each other.

by Jen Tota McGivney

The National Cancer Institute and the Food and Drug Administration have provided guidance for managing clinical trials amid the spread of the novel coronavirus. Cancer centers are making changes to care for some patients enrolled in trials.

by Anna Azvolinsky